- Amgen expands crackdown on what it says is misuse of 340B programAmgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud…Endpoints · 2mo ago↗ source
- Candel reports prostate cancer drug's long-term data ahead of FDA filingCandel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…Endpoints · 2mo ago↗ source
- Post-Hoc Live: Makary's out at FDA and what comes nextMarty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. Makary was scheduled to sit down with senior reporter Max Bayer this week at ...